Does the term trophic actually mean anti-amyloidogenic the case of NGF

Cell Death and Differentiation

Volumn 17, Issue 7, 2010, Pages 1126-1133

  Calissano, P ^a,b,c   Amadoro, G ^a   Matrone, C ^a   Ciafre S ^a   Marolda, R ^a   Corsetti, V ^a   Ciotti, M T ^a   Mercanti, D ^a   Di Luzio, A ^a   Severini, C ^a   Provenzano, C ^a   Canu, N ^a,c  

^a Institute of Neurobiology and Molecular Medicine   (Italy)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

amyloid; Alzheimer's disease; Apoptosis; NGF; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PHOSPHOLIPASE C GAMMA; PRESENILIN 1; PROTEIN TYROSINE KINASE A; TAU PROTEIN;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; APOPTOSIS; DRUG HALF LIFE; DRUG PENETRATION; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; SENILE PLAQUE; ANIMAL; CYTOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOPTOSIS; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEURONS; RATS; RECEPTOR, TRKA;

EID: 77953619382     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.38     Document Type: Review

References (88)

1. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcoma AS 37 and 180. Proc Natl Acad Sci USA 1954; 40: 1014-1018.
2. Levi-Montalcini R. Nerve growth factor. Science 1975; 187: 113.
3. Cohen S, Levi-Montalcini R. A nerve growth-stimulating factor isolated from snake venom. Proc Natl Acad Sci USA 1956; 42: 571-574.
4. Levi-Montalcini R, Booker B. Destruction of the sympathetic ganglia in mammals by antiserum to a nerve growth protein. Proc Natl Acad Sci USA 1960; 46: 384-391.
5. Levi-Montalcini R, Calissano P. The nerve growth factor as a paradigm of polypeptide growth factors. Trends Neurosci 1986; 8: 473-477.
6. Claude P, Hawrot E, Dunis DA, Campenot RB. Binding, internalization, and retrograde transport of 125I-nerve growth factor in cultured rat sympathetic neurons. J Neurosci 1982; 2: 431-442. (Pubitemid 12040429)
7. Yip HK, Rich KM, Lampe PA, Johnson Jr EM. The effects of nerve growth factor and its antiserum on the postnatal development and survival after injury of sensory neurons in rat dorsal root ganglia. J Neurosci 1984; 4: 2986-2992.
8. Walsh DM, Selkoe DJ. Ab oligomers-a decade of discovery. J Neurochem 2007; 101: 1172-1184. Review.
9. Eckman CB, Eckman EA. An update on the amyloid hypothesis. Neurol Clin 2007; 25: 669-682. Review.
10. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
11. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766. Review.
12. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181-193. Review.
13. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008; 283: 29615-29619.
14. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etio-pathogenesis, therapeutics and prevention. J Cell Mol Med 2008; 12: 38-55. Review.
15. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112. Review.
16. Götz J, Ittner LM, Schonrock N, Cappai R. An update on the toxicity of Ab in Alzheimer's disease. Neuropsychiatr Dis Treat 2008; 4: 1033-1042.
17. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002; 99: 6364-6369.
18. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754.
19. King ME, Kan HM, Baas PW, Erisir A, Glabe C, Bloom G. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006; 20: 541-546.
20. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005; 1739: 280-297.
21. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-778. Review.
22. Calissano P, Matrone C, Amadoro G. Apoptosis and in vitro Alzheimer disease neuronal models. Comm Integr Biol 2009; 2: 163-169.
23. Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 2009; 4: 48.
24. Hu NW, Smith IM, Walsh DM, Rowan MJ. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 2008; 131 (Part 9): 2414-2424.
25. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-344. Review.
26. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-1058.
27. Lee HG, Moreira PI, Zhu X, Smith MA, Perry G. Staying connected: synapses in Alzheimer disease. Am J Pathol 2004; 165: 1461-1464. Review.
28. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
29. D'Mello S, Galli C, Ciotti MT, Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci USA 1993; 90: 10989-10993.
30. Borsello T, Di Luzio A, Ciotti MT, Calissano P, Galli C. Granule neuron DNA damage following deafferentation in adult rats cerebellar cortex: a lesion model. Neuroscience 2000; 95: 163-171.
31. Cavallaro S, Calissano P. A genomic approach to investigate neuronal apoptosis. Curr Alzheimer Res 2006; 3: 4-23.
32. Galli C, Meucci O, Scorziello A, Werge TM, Calissano P, Schettini G. Apoptosis in cerebellar granule cells is blocked by high KCI, Forskolin, and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis. J Neurosci 1995; 15: 1172-1179.
33. Galli C, Piccini A, Ciotti MT, Castellani L, Calissano P, Zaccheo D et al. Increased amyloidogenic secretion in cerebellar granule cells undergoing apoptosis. Proc Natl Acad Sci USA 1998; 95: 1247-1252. (Pubitemid 28124944)
34. Canu N, Dus L, Barbato C, Ciotti MT, Brancolini C, Rinaldi AM et al. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci 1998; 18: 7061-7074.
35. Amadoro G, Serafino AL, Barbato C, Ciotti MT, Sacco A, Calissano P et al. Role of N-terminal tau domain integrity on the survival of cerebellar granule neurons. Cell Death Differ 2004; 11: 217-230.
36. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci USA 2006; 103: 2892-2897.
37. Atlante A, Gagliardi S, Marra E, Calissano P. Neuronal apoptosis in rats is accompanied by rapid impairment of cellular respiration and is prevented by scavengers of reactive oxygen species. Neurosci Lett 1998; 245: 127-130.
38. Bobba A, Atlante A, Giannattasio S, Sgaramella G, Calissano P, Marra E. Early release and subsequent caspase-mediated degradation of cytochrome c in apoptotic cerebellar granule cells. FEBS Lett 1999; 457: 126-130.
39. Atlante A, De Bari L, Bobba A, Marra E, Calissano P, Passarella S. Cytochrome c, released from cerebellar granule cells undergoing apoptosis or excytotoxic death, can generate protonmotive force and drive ATP synthesis in isolated mitochondria. J Neurochem 2003; 86: 591-604.
40. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 2000; 20: 589-599.
41. Canu N, Tufi R, Serafino AL, Amadoro G, Ciotti MT, Calissano P. Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. J Neurochem 2005; 92: 1228-1242.
42. De Berardinis MA, Ciotti MT, Amadoro G, Galli C, Calissano P. Transfer of the apoptotic message in sister cultures of cerebellar neurons. Neuroreport 2001; 12: 2137-2140.
43. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424-2428.
44. Kuo M, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-4081.
45. Matrone C, Di Luzio A, Meli G, D'Aguanno S, Severini C, Ciotti MT et al. Activation of the amyloidogenic route by NGF deprivation induces apoptotic death in PC12 cells. J Alzheimers Dis 2008; 13: 81-96.
46. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999; 97: 395-406.
47. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 2007; 54: 721-737.
48. Corsetti V, Amadoro G, Gentile A, Capsoni S, Ciotti MT, Cencioni MT et al. Identification of a caspase-derived N-terminal tau fragment in cellular and animal Alzheimer's disease models. Mol Cell Neurosci 2008; 38: 381-392.
49. Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res 2002; 136: 467-486.
50. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006; 9 (3 Suppl): 101-115.
51. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006; 27: 1372-1384.
52. Frielingsdorf H, Simpson DR, Thal LJ, Pizzo DP. Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis 2007; 26: 47-55.
53. Matrone C, Ciotti MT, Mercanti D, Marolda R, Calissano P. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc Natl Acad Sci USA 2008; 105: 13139-13144.
54. Amadoro G, Corsetti V, Ciotti MT, Florenzano F, Capsoni S, Amato G et al. Endogenous Abeta causes cell death via early tau hyperphosphorylation. Neurobiol Aging 2009. (doi:10.1016/j.neurobiolaging.2009.06.005).
55. Bhat RV, Leonov S, Luthman J, Scott CW, Lee CM. Interactions between GSK3beta and caspase signaling pathways during NGF deprivation induced cell death. J Alzheimers Dis 2002; 4: 291-301.
56. Shelton SB, Johnson GV. Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. J Neurosci Res 2001; 66: 203-213.
57. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006; 83: 374-384.
58. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332.
59. Capsoni S, Giannotta S, Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol Cell Neurosci 2002; 21: 15-28.
60. Capsoni S, Giannotta S, Cattaneo A. Early events of Alzheimer-like neurodegeneration in anti-nerve growth factor transgenic mice. Brain Aging 2002; 2: 24-43.
61. Ruberti F, Capsoni S, Comparini A, Di Daniel E, Franzot J, Gonfloni S et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J Neurosci 2000; 20: 2589-2601.
62. Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G et al. Interaction of tau protein with the dynactin complex. EMBO J 2007; 26: 4546-4554.
63. Tatebayashi Y, Haque N, Tung YC, Iqbal K, Grundke-Iqbal I. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci 2004; 117: 1653-1663.
64. Niewiadomska G, Baksalerska-Pazera M, Riedel G. Cytoskeletal transport in the aging brain: focus on the cholinergic system. Rev Neurosci 2006; 17: 581-618.
65. Niewiadomska G, Baksalerska-Pazera M, Riedel G. Altered cellular distribution of phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats. Ann N Y Acad Sci 2005; 1048: 287-295.
66. Chao MV. Neurotrophins and their receptors: a convergence point for many signaling pathways. Nat Rev Neurosci 2003; 4: 299-309. Review.
67. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609-642.
68. Matrone C, Marolda R, Ciafrè S, Ciotti MT, Mercanti D, Calissano P. Tyrosine kinase NGF receptor switches from a pro-survival to a pro-apoptotic activity via Abeta-mediated phosphorylation. Proc Natl Acad Sci USA 2009; 106: 11358-11363.
69. Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 2008; 283: 18177-18186.
70. Russo C, Dolcini V, Salis S, Venezia V, Violani E, Carlo P et al. Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. J Biol Chem 2002; 277: 35282-35288.
71. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004; 10: 452-458. Review.
72. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci 2002; 22: 10-20.
73. Zampieri N, Xu CF, Neubert TA, Chao MV. Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. J Biol Chem 2005; 280: 14563-14571.
74. Li H, Wolfe MS, Selkoe DJ. Toward structural elucidation of the gamma-secretase complex. Structure 2009; 17: 326-334. Review.
75. Coulson EJ, May LM, Sykes AM, Hamlin AS. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease. Neuroscientist 2009; 15: 317-323.
76. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 2009; 28: 3941-3946.
77. Longo FM, Massa SM. Neurotrophin receptor-based strategies for Alzheimer's disease. Curr Alzheimer Res 2005; 2: 167-169. Review.
78. Castellani RJ, Zhu X, Lee HG, Moreira PI, Perry G, Smith MA. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? Expert Rev Neurother 2007; 7: 473-485.
79. Tuszynski MH. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2007; 21: 179-189.
80. Bergami M, Rimondini R, Santi S, Blum R, Götz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci USA 2008; 105: 15570-15575.
81. Covaceuszach S, Capsoni S, Marinelli S, Pavone F, Ceci M, Ugolini G et al. In vitro receptor binding properties of a 'painless' NGF mutein, linked to hereditary sensory autonomic neuropathy type V. Biochem Biophys Res Commun 2010; 391: 824-829.
82. Johnson A. Ganstigmine. Chiesi. Curr Opin Investig Drugs 2003; 4: 868-873.
83. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
84. Longo FM, Yang T, Knowles JK, Xie Y, Moore LA, Massa SM. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. Curr Alzheimer Res 2007; 4: 503-506. Review.
85. Pehar M, Cassina P, Vargas MR, Xie Y, Beckman JS, Massa SM et al. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur J Neurosci 2006; 24: 1575-1580.
86. Mahoney MJ, Saltzman WM. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. J Pharm Sci 1996; 85: 1276-1281.
87. Gu H, Long D, Song C, Li X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci Lett 2009; 453: 204-209.
88. Montalcini RL, Calissano P. The Nerve Growth Factor. Sci Am 1979; 240; 68-77.